Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Diacerein

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 384Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science
    Castle Creek Pharmaceutical Holdings Completes Acquisition of Fibrocell Science

    13 Dec 2019

    // PRESS RELEASE

    https://www.castlecreekpharma.com/castle-creek-pharmaceutical-holdings-completes-acquisition-of-fibrocell-science/

    PRESS RELEASE
    13 Dec 2019
    Share Share
    Castle Creek Pharmaceutical Holdings Announces Agreement to Acquire Fibrocell
    Castle Creek Pharmaceutical Holdings Announces Agreement to Acquire Fibrocell

    14 Sep 2019

    // BIOSPACE

    https://www.biospace.com/article/releases/castle-creek-pharmaceutical-holdings-announces-agreement-to-acquire-fibrocell/?s=79

    BIOSPACE
    14 Sep 2019
    Share Share
    Castle Creek Pharma Receives $71.8m in Funding
    Castle Creek Pharma Receives $71.8m in Funding

    24 Oct 2018

    // FINSMES

    http://www.finsmes.com/2018/10/castle-creek-pharma-receives-71-8m-in-funding.html

    FINSMES
    24 Oct 2018
    Share Share
    Fresh from $72M raise, New lead rare disease drug flagged as failure
    Fresh from $72M raise, New lead rare disease drug flagged as failure

    23 Oct 2018

    // John Carroll ENDPTS

    https://endpts.com/fresh-from-a-72m-raise-jeff-aronins-new-lead-rare-disease-drug-is-flagged-as-a-failure/

    John Carroll ENDPTS
    23 Oct 2018
    Share Share
    Castle Creek Pharmaceuticals Receives FDA FT Designatn for Diacerein 1% Ointment
    Castle Creek Pharmaceuticals Receives FDA FT Designatn for Diacerein 1% Ointment

    09 Aug 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/castle-creek-pharmaceuticals-receives-fda-fast-track-designation-for-diacerein-1-ointment-for-treatment-of-epidermolysis-bullosa-simplex-300694583.html

    PR NEWSWIRE
    09 Aug 2018
    Share Share
    Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation
    Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation

    16 May 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/castle-creek-pharmaceuticals-receives-fda-rare-pediatric-disease-designation-for-diacerein-1-ointment-for-epidermolysis-bullosa-300649448.html

    PR NEWSWIRE
    16 May 2018
    Share Share